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lescents with ADHD, using the comprehensive medical claims
database of Nordbaden/Germany, covering an insured popula-
tion of 2.234 m (hereof, 468,000 children and adolescents) in
2003. METHODS: A total of 11,245 children and adolescents
with a diagnosis of ADHD (ICD-10-codes for “Hyperkinetic
Disorder”, F90.0, F90.1) were identiﬁed. For a retrospective
analysis of methylphenidate prescriptions by age, gender, and
comorbid conduct disorder, administrative data from the orga-
nization of licensed physicians (Kassenaerztliche Vereinigung) 
in Nordbaden/Germany were combined with data from the
regional vdak, an association of statutory sick funds. RESULTS:
For the regional population, methylphenidate treatment preva-
lence rates were approximately 1.7% (children) and 0.6% (ado-
lescents). Among those with a diagnosis of ADHD, 4.3% of
preschoolers (age 0–6) were administered methylphenidate.
Among children (age 7–12), 35.1% (95%-CI, 33.0%–37.1%)
were prescribed methylphenidate; in adolescents (age 13–19),
this rate increased to 46.2% (42.7%–49.8%). Across ADHD
groups analyzed, children with concomitant conduct disorder
(42.4%; 39.4%–45.5% versus 27.9%; 26.2%–29.7%), and
boys (34.4%; 32.6%–36.2% versus girls: 25.5%; 22.7%–
28.4%) were more likely to be treated with methylphenidate.
Very few patients (<1%) received higher doses than recom-
mended. Child and adolescent psychiatrists accounted for 35%
of methylphenidate prescriptions for patients with ADHD 
(pediatricians, 40%; general practitioners, 12%). During 2003, 
the number of deﬁned daily doses prescribed in Nordbaden
increased by a compound annual growth rate of 27%. CON-
CLUSIONS: Though methylphenidate prescriptions continued
to increase during 2003, the present data do not provide 
evidence for overuse. Of note, a limitation of administrative
database analyses is lack of information on the accuracy of diag-
noses.—The low rate of methylphenidate prescriptions for
preschoolers corresponds to clinical guidelines.
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OBJECTIVES: To estimate the cost-effectiveness of adding epti-
ﬁbatide to medical therapy (aspirin, heparin, thienopyridine) in
acute coronary syndrome patients undergoing percutaneous
coronary intervention (PCI; including stent procedures) who are
at high risk of subsequent myocardial infarction (MI), target
vessel revascularization (TVR) or cardiovascular death, from a
hospital perspective. METHODS: A Markov model was con-
structed to evaluate eptiﬁbatide (two i.v.-injections of 180 μg/kg,
followed by an i.v.-infusion of 2.0 μg/kg/min for 18–24 h) versus
placebo in addition to aspirin, heparin, and thienopyridine
(mostly clopidogrel, oral loading dose 300 mg) before PCI. The
model has 4 disease states (no event, post-MI, post-TVR, death),
two tunnel states (TVR, non-fatal MI) and runs for the expected
lifetime of the patient. Patient’s history of TVR and MI is
tracked. The effectiveness parameters were taken from the 1-year
ESPRIT clinical trial and extrapolated with an estimated Weibull
function. Direct medical costs in 2006 prices were considered
from a hospital perspective. Resource utilization was based on
hospital expert-elicited treatment patterns from three German
urban hospitals and was valued with averaged prices of these
hospitals. Utilities were derived from published literature. Future
costs and effects were discounted at 5%. RESULTS: When com-
pared to treatment with aspirin, heparin, and thienopyridine,
adding eptiﬁbatide before PCI renders incremental net savings of
€927 and provides an additional 0.06 QALY per patient. Simi-
larly, treating 1000 patients additionally with eptiﬁbatide before
PCI avoids 11 fatal and 44 non-fatal MIs, but leads to 7 addi-
tional TVRs due to increased survival. Were there no differences
in survival, eptiﬁbatide would avoid 45 non-fatal MIs and 1
TVR. These results are sensitive to the price and effectiveness of
eptiﬁbatide. CONCLUSIONS: Adding eptiﬁbatide before PCI in
the investigated patient population (at high risk of subsequent
MI, TVR and death) seems to substantially reduce hospital costs
and increase patient relevant health outcomes.
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OBJECTIVES: The current diagnostic management of patients
with palpitations sometimes fails to establish a diagnosis. The
aim of the Recurrent Unexplained Palpitations (RUP) study was
to compare the diagnostic yield and the costs of prolonged 
monitoring strategy using an implantable loop recorder (ILR)
with that of conventional diagnostic testing, in patients with
infrequent unexplained palpitations. METHODS: RUP is a mul-
ticentrer, prospective, randomized study. We studied 50 consec-
utive patients (mean age 55 ± 18 years, 33 females) without or
with only mild heart disease, and with clinically signiﬁcant, infre-
quent (>=1 episode per month), sustained (>1 minute) palpita-
tions. Before enrolment, patients had a negative initial evaluation
including ECG, 24 hour Holter monitoring, and blood chemistry
examinations. Enrolled patients were randomized either to con-
ventional strategy (n = 24) or to ILR implantation (n = 26). In
order to evaluate the cost-effectiveness of ILR strategy, full hos-
pital cost of procedures was calculated. RESULTS: In the con-
ventional testing group a diagnosis was obtained in 5 patients (1
atrial ﬁbrillation, 4 supraventricular tachycardia). In the ILR
group a diagnosis was obtained in 19 subjects (2 sinus rhythm,
6 supraventricular tachycardia, 4 sinus tachycardia, 4 atrial 
ﬁbrillation, 2 atrial ﬂutter, 1 paroxysmal AV block). Thus, the
diagnostic yield of ILR was signiﬁcantly higher respect to con-
ventional strategy (73% vs 21%, p < 0.001). The average cost
per patient was €1.410 in the conventional strategy group and
€2.233 in the ILR group (p < 0.001). Considering the total cost
for each group, the cost per diagnosis was €6.767 and €3.056
respectively. CONCLUSIONS: The ICER obtained is low if com-
pared to further examinations and acute events management nec-
essary in case of less of diagnosis. The results of cost-effectiveness
analysis could be useful to design further research protocols. Fur-
thermore, these results could help decision makers to allocate
resources based on cost-effectiveness evidences.
